To evaluate the importance of EIF4A3 for clinical application in immunotherapy, we acquired the expression and therapeutic effect data of an open-source clinical study on anti-PD-L1 therapy for uroepithelial carcinoma, published in 2018 (Mariathasan et al., 2018). Here, CD274 is linked to urothelial carcinoma.